Table 3.
Clinical characteristics of St Mark’s Hospital blood donors and healthy volunteers.
| Characteristic | HC | CD | UC |
|---|---|---|---|
| n | 18 | 17 | 14 |
| Male/female | 13/5 | 8/9 | 7/7 |
| Median age [95% CI] at sampling | 41.5 [30–54] | 43.5 [33–61] | 54.5 [35–63] |
| Median age [95% CI] at diagnosis | 25 [20–44] | 38.5 [25–47] | |
| Symptoms at sampling: | |||
| Diarrhoea/loose stools | 1 | 2 | |
| Occasional loose motion/watery stool | 2 | 1 | |
| A bdominal pain | 2 | 1 | |
| Perianal pain/itch/disease | 2 | 1 | |
| Lethargy | 2 | 0 | |
| Proctitis | 0 | 1 | |
| None | 9 | 8 | |
| IBD medications at sampling: | |||
| Aminosalicylates | 8 | 8 | |
| Azathioprine/6-mercaptopurine | 8 | 2 | |
| Corticosteroids | 1 | 0 | |
| Vedolizumab | 1 | 0 | |
| Antibiotics | 1 | 0 | |
| Methotrexate | 1 | 0 | |
| None | 1 | 6 | |
| Non-IBD medications at sampling: | |||
| Vitamins D/D3/B12/multi | 4 | 3 | |
| Metformin/gliclazide | 0 | 2 | |
| Statins | 1 | 2 | |
| Hydroxychloroquine | 0 | 1 | |
| Proton pump inhibitor | 0 | 1 | |
| Alendronate | 1 | 0 | |
| Finasteride | 1 | 0 | |
| Loperamide | 1 | 1 | |
| None | 12 | 9 |
Demographic and clinical data analysed in Figures 4, 5, amd Figs S2, S3, S4, available as Supplementary data at ECCO-JCC online.
HC, healthy controls; CD, Crohn’s disease; UC, ulcerative colitis; IBD, inflammatory bowel disease; CI, confidence interval.